Lessons from the early days of chimeric antigen receptor (CAR) T-cell therapy remain fresh as Kite Pharma prepares for the FDA to act on its supplemental biologics license application for use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results